Press ReleaseJun | 25 | 2020
Impaired blood clotting after surgery or major injury can lead to severe bleeding or hemorrhage in patients if they are not rapidly treated with blood transfusions.
A team led by investigators at Massachusetts General Hospital has developed a novel, inexpensive and portable device that can quickly and accurately measure the ability of blood to properly clot (or coagulate).
Traditional laboratory tests for clotting defects take several hours to measure and are often not reflective of the clotting state at the time of transfusion, but the new test—called iCoagLab—instead reports several coagulation metrics within minutes.
The iCoagLab test involves the use of an inexpensive laser that can illuminate a few drops of blood taken from a patient. Fluctuations made visible by the laser indicate whether the blood can properly clot.
In the new study, which is published in the journal Thrombosis and Haemostasis, iCoagLab was compared with a conventional test for clotting defects and applied to blood samples from 270 patients. Clotting parameters included reaction time, clot progression time, clot progression rate and maximum clot strength.
In all patients, there was good correlation between iCoagLab results and conventional test results. Analyses revealed that iCoagLab was as sensitive at detecting bleeding risk as the conventional test, and it had a higher accuracy.
The researchers have recently developed a hand-held version of the technology that will allow clinicians to simply place a drop of blood into a disposable cartridge to generate results within minutes at a patient’s bedside.
“Clinicians in the operating room or the ICU often walk a thin line to maintain the delicate balance between bleeding and coagulation,” said senior author Seemantini K. Nadkarni, PhD, an associate professor at Harvard Medical School and director of the Nadkarni Laboratory for Optical Micromechanics and Imaging at the Wellman Center for Photomedicine at Mass General.
“The iCoagLab innovation will likely advance clinical capability to rapidly identify patients with defective clotting at the point-of-care, assess risk of hemorrhage, and tailor treatments based on individual coagulation deficits to help prevent life-threatening bleeding in patients.”
Paper Cited: Tripathi MM, Tshikudi DM, Hajjarian Z, Hack DC, Van Cott EM, Nadkarni SK. Comprehensive Blood Coagulation Profiling in Patients Using iCoagLab: Comparison Against Thromboelastography [published online ahead of print, 2020 Jun 22]. Thromb Haemost. 2020;10.1055/s-0040-1712956. doi:10.1055/s-0040-1712956
Funding: The research was supported by funding from the National Heart, Lung, and Blood Institute, the National Institute of Biomedical Imaging and Bioengineering and the Air Force Office of Scientific Research.
About Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2019, Mass General was named #2 in the U.S. News & World Report list of "America’s Best Hospitals."
Our research integrates the full spectrum of "bench to bedside" discovery where lab scientists work alongside clinicians to improve patient care.
Mass General Brigham is proud to announce the award of $6 million to 35 organizations dedicated to improving both mental and behavioral health outcomes, as well as promoting economic mobility and financial stability in the communities we serve.
Massachusetts General Hospital has received a transformational gift of $100 million from entrepreneur, philanthropist, and proud Bostonian, Herb Chambers in support of a new state-of-the-art building designed to meet the growing demand for world-class cancer care.
New study shows that being sedentary increases the risk of the most common types of heart disease, even among those who get enough exercise
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
The 2024 class of awardees will receive more than $6 million in funding to accelerate groundbreaking cancer research.
Mass General Brigham researchers found that getting vaccinated on the early side of the recommended window was best for transferring maternal antibodies to the fetus.
